Member Info for Valhalla14

Hilarious

We invest money into a loss making company.....so then we invest into the same loss making company again ffs.....then the CEO leaves the company

Jarv55 We all know broker targets are very rarely hit.....VERY RARELY

Typical rookie answer Bouunceback......absolute ROOKIE

FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End Investments

12 May 2020

FastForward Innovations Ltd

("FastForward", "FFWD" or the "Company")



Investee Company Update: Portage Biotech Inc.



FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, is pleased to note the following announcement released on 11 May 2020 concerning investee company Portage Biotech Inc. ("Portage"). FastForward has a 1.18% interest in the issued stock of Portage.



The announcement is set out below without material changes or adjustments.



Portage Biotech Inc.

('Portage' or the 'Group')

Portage Makes Additional Investment in Stimunity S.A.S, a Parasbased Cancer Immunotherapy Company

· Stimunity hits developmental milestone

· Developed systemic delivery for STING pathway

· Additional €900k invested

Toronto, Ontario, May 11, 2020 - Portage Biotech Inc. ("Portage" or "the Company") (Canadian Securities Exchange: PBT.U, OTC Markets : PTGEF), is pleased to announce that It has made an additional €900k investment in its associate, Stimunity, the Paris-based cancer immunotherapy company focused on STING. Stimunity has reached a major milestone in its preclinical development plan and the additional financing will enable it to start the manufacturing of its biologic cGAMP-VLP (STI-001) lead compound.

"We knew since the beginning of the company that STING-activating cGAMP Virus-Like Particle (cGAMP-VLP) technology has a unique property enabling its payload to preferentially target immune cells, which is different from other chemical STING approaches. This has an impact on the stimulation of the immune system and the quality of the anti-tumoral response. We have determined that this targeting mechanism is able to deliver the cGAMP via systemic route of administration and that it leads to induction of systemic anti-tumor T-cell response" says Nicolas Manel, co-founder and Scientific Advisor of the company.

"These new data demonstrate that picking the right approach to modulate STING is key. The use of VLP carrier enables a simple systemic approach to deliver STING modulation directly to immune cells. Portage is pleased with the work performed by Stimunity and this new round of financing will support the progress toward clinical trials" says Dr. Ian Walters, Chairman of Stimunity's Supervisory Board and CEO of Portage.

For additional details, please see the press release issued by Stimunity at https://stimunity.com/static/Stimunity_Milestone2_2020_VF.pdf

Been down 20% on many shares and just rode it out....don't believe all you read in books....plenty of trades go south but if the fundamentals still remain the same then there's no need to bail out at a loss

7 May 2020

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")



Exercise of Options and Total Voting Rights



Omega Diagnostics (AIM: ODX), the medical diagnostics company focused CD4, infectious diseases, food intolerance and allergy testing, announces that it has allotted 75,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options by employees.

Application has been made to the London Stock Exchange for the 75,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 13 May 2020.



After Admission, the total number of Ordinary Shares in issue will be 150,552,010 and the total number of voting rights will therefore be 150,552,010. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Just shows how green most of the newbies are on this BB....

TIZIANA LIFE SC
TILS
65.00 +7.50 (+13.04%)

Forms 8.3 and 8.5 are disclosure forms required by the Takeover Panel to clarify material interests in the share register of a UK-listed company that is in a bid situation. Any person or institution that has an interest of more than 1% of the share capital of a company in a bid situation (on both sides of the transaction) must disclose any dealings in those shares and their resultant position.

Form 8.3 should be completed by the shareholder to clarify what they have bought or sold and the resultant size of their stake. Form 8.5, meanwhile, should be completed by any principal trader that has dealt in the shares.

These disclosure forms are required as part of the Takeover Code which aims to ensure an orderly framework within which takeovers can be conducted fairly and appropriately.

Gaps in and there are plenty to fill....agreed that someone is accumulating here on the quiet

When a company does this time and time again its a DOG and a big AVOID

AMIGO The UK's Leading "Guarantor" Loan Provider
Run along now tome1985 that's hilarious!

Overhang needs to clear

Legal & General selling....will move when they clear

Alva-based medical testing company Omega Diagnostics has signed an agreement to provide manufacturing capability for a Covid-19 antibody test, saying it will produce up to 46,000 of the kits a day

Buy to me when BOD members are selling....looks more like ramp the SP up and bail out

Oldapache all the information is there to see in the RNS section CLN's and warrants need to clear before this moves so it is being held in a range to clear them...hence the spread

Fri, 24th Apr 2020 07:00
RNS Number : 7248K
Tiziana Life Sciences PLC
24 April 2020




Tiziana Life Sciences plc

("Tiziana" or the "Company")

Issue of Equity and Resulting Total Voting Rights. Update on AIM cancellation and migration to Nasdaq.

London, New York, 24 April 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has allotted and issued a total of 6,118,797 ordinary shares of 3 pence each ("Ordinary Shares") credited as fully paid in respect of (i) the conversion of £1,595,322 in face value of its outstanding convertible notes at a conversion price of 42 pence per share (including accrued interest of 16 per cent.); and (ii) the exercise of 1,712,672 warrants at a price of 35 pence per share, yielding £599,435.20 in cash proceeds for the Company and retiring £1,595,322 of indebtedness.

Application has been made for the 6,118,797 new Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are expected to commence on or around 30 April 2020. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

Total Voting Rights

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary Shares and that following the issue of the Ordinary Shares to be issued in connection with the conversion of the loan notes and the exercise of the warrants, the total number of Ordinary Shares in issue is 160,516,883. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

of folk suckered in over the last few days....rinse and repeat....tut...tut....tut!

Is back ;o) 12:22:56 64.50 100,000 64.50k O